Inactive Instrument

ENTST BIO Stock Other OTC

Investment Holding Companies

End-of-day quote Other OTC Other stock markets
- ^USD	-

21/01/20	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
20/12/19	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI

Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Cap	541K 473K 436K 402K 758K 52.09M 775K 5.21M 2.05M 25.51M 2.03M 1.99M 87.82M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 491K 453K 418K 787K 54.13M 805K 5.42M 2.13M 26.51M 2.11M 2.06M 91.26M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

21/01/20	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
20/12/19	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
15/07/19	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
23/01/19	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
04/12/18	Entest Group, Inc. Announces Management Changes	CI
27/11/18	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
20/11/18	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
14/02/18	ENTB will Change its Name to ETNI	CI
27/11/15	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/08/15	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
27/07/15	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
16/07/14	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
06/03/13	Entest Biomedical Mulls Acquisitions	CI

21/01/20	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
08/01/20	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
20/12/19	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
10/05/18	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
13/09/17	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHURCHILL CAPITAL CORP XI	-0.96%	-6.95%	-	-	806M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.10%	-0.20%	-	-	642M
DEEP FISSION, INC.	+1.33%	-4.14%	-	-	643M
CHURCHILL CAPITAL CORP XII	+0.56%	+0.85%	-	-	611M
CANTOR EQUITY PARTNERS IV, INC.	-0.14%	-0.05%	-	-	596M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	-0.44%	-	-	596M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-1.53%	-1.53%	-	-	575M
CENTIEL AG	-2.80%	+8.17%	+241.94%	-71.63%	563M
Average	-0.47%	-0.54%	+241.94%	-71.63%	628.96M
Weighted average by Cap.	-0.44%	-0.88%	+241.94%	-71.63%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.29M -1.19M -1.1M -2.07M -142M -2.12M -14.24M -5.6M -69.68M -5.55M -5.43M -240M	192K 167K 155K 142K 268K 18.45M 274K 1.85M 726K 9.04M 720K 704K 31.11M
Net Debt	19.4K 16.95K 15.64K 14.42K 27.18K 1.87M 27.78K 187K 73.55K 915K 72.86K 71.26K 3.15M	21.2K 18.52K 17.09K 15.76K 29.7K 2.04M 30.36K 204K 80.36K 1M 79.61K 77.86K 3.44M

ENTST BIO Stock Other OTC

Stocks

Investment Holding Companies

Valuation: ENTST BIO

Latest news : ENTST BIO

Press Releases: ENTST BIO

Managers and Directors: ENTST BIO

Shell Companies

Financials

Company Profile